• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed

    3/2/21 3:33:11 PM ET
    $SYN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SYN alert in real time by email
    SC 13D/A 1 sc13da112227005_03022021.htm AMENDMENT NO. 1 TO THE SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 1)1

    Synthetic Biologics, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    87164U201

    (CUSIP Number)

    David Elliot Lazar

    c/o Custodian ventures llc

    1185 Avenue of the Americas, 3rd Floor

    New York, New York 10036

    (646) 768-8417

     

    Spencer G. Feldman, ESQ.

    OLSHAN FROME WOLOSKY LLP

    1325 Avenue of the Americas

    New York, New York 10019

    (212) 451-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    February 18, 2021

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 87164U201

      1   NAME OF REPORTING PERSON  
             
            CUSTODIAN VENTURES LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Wyoming  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         2,224,500  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              2,224,500  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,224,500  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            2.1%  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    2

    CUSIP No. 87164U201

      1   NAME OF REPORTING PERSON  
             
            DAVID ELLIOT LAZAR  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         2,224,500  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              2,224,500  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,224,500  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            2.1%  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    3

    CUSIP No. 87164U201

    The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned (“Amendment No. 1”). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein. As a result of an increase in the outstanding Shares of the Issuer from 19,993,390 as of November 6, 2020 as reported in the Issuer’s Form 10-Q for the nine months ended September 30,2020 to 105,223,086 Shares outstanding as described below, the Reporting Persons ceased to beneficially own more than 5% of the outstanding Shares.

     

    Item 3.Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended and restated to read as follows:

    The Shares purchased by Custodian were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in open market purchases, except as otherwise noted. The aggregate purchase price of the 2,224,500 Shares directly beneficially owned by Custodian is approximately $897,996 excluding brokerage commissions.

    Item 5.Interest in Securities of the Issuer.

    Items 5(a) – (c) and (e) are hereby amended and restated to read as follows:

    The aggregate percentage of Shares reported owned by each person named herein is based upon 105,223,086 Shares outstanding, which is the total number of Shares outstanding as of February 18, 2021, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 19, 2021.

    A.Custodian
    (a)As of the close of business on March 1, 2021, Custodian directly beneficially owned 2,224,500 Shares.

    Percentage: Approximately 2.1%

    (b)1. Sole power to vote or direct vote: 0
    2. Shared power to vote or direct vote: 2,224,500
    3. Sole power to dispose or direct the disposition: 0
    4. Shared power to dispose or direct the disposition: 2,224,500

     

    (c)The transactions in the Shares by Custodian since the filing of Schedule 13D are set forth in Schedule A and are incorporated herein by reference.
    B.Mr. Lazar
    (a)Mr. Lazar, as the sole member and Chief Executive Officer of Custodian, may be deemed the beneficial owner of the 2,224,500 Shares owned by Custodian.

    Percentage: Approximately 2.1%

     

    (b)1. Sole power to vote or direct vote: 0
    2. Shared power to vote or direct vote: 2,224,500
    3. Sole power to dispose or direct the disposition: 0
    4. Shared power to dispose or direct the disposition: 2,224,500

     

    4

    CUSIP No. 87164U201

    (c)Mr. Lazar has not entered into any transactions in the Shares since the filing of the Schedule 13D. The transactions in the Shares on behalf of Custodian since the filing of Schedule 13D are set forth in Schedule A and are incorporated herein by reference.

    The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

    (e)As of February 18, 2021, the Reporting Persons ceased to beneficially own more than 5% of the outstanding Shares.

     

    5

    CUSIP No. 87164U201

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: March 2, 2021

     

      CUSTODIAN VENTURES LLC
       
      By:

    /s/ David Elliot Lazar

        Name: David Elliot Lazar
        Title: Chief Executive Officer
           
           
     

    /s/ David Elliot Lazar

      David Elliot Lazar

     

    6

    CUSIP No. 87164U201

     

    SCHEDULE A

     

    Transaction in the Shares Since the Filing of the Schedule 13D

     

    Nature of Transaction

    Shares of Common Stock

    Purchased/(Sold)

    Price Per

    Share($)

    Date of

    Purchase/Sale

     

    Custodian Ventures LLC

     

    Purchase of Common Stock 10,000 0.6199 02/23/2021
    Purchase of Common Stock 30,000 0.6199 02/23/2021
    Purchase of Common Stock 30,000 0.6170 02/23/2021
    Purchase of Common Stock 20,000 0.6182 02/23/2021
    Purchase of Common Stock 30,000 0.7035 02/23/2021
    Purchase of Common Stock 20,000 0.6999 02/25/2021
    Purchase of Common Stock 20,000 0.7003 02/25/2021
    Purchase of Common Stock 65,000 0.6903 02/25/2021
    Purchase of Common Stock 20,000 0.7027 02/26/2021
    Purchase of Common Stock 15,000 0.6969 02/26/2021

     

     

    Get the next $SYN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SYN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Shallcross Steven A

      4 - Theriva Biologics, Inc. (0000894158) (Issuer)

      12/15/23 4:07:49 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Wolf Jeffrey Alan

      4 - Theriva Biologics, Inc. (0000894158) (Issuer)

      12/15/23 4:01:42 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Monahan John J

      4 - Theriva Biologics, Inc. (0000894158) (Issuer)

      12/15/23 4:00:19 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYN
    SEC Filings

    See more
    • Synthetic Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Theriva Biologics, Inc. (0000894158) (Filer)

      2/7/24 8:10:24 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synthetic Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Theriva Biologics, Inc. (0000894158) (Filer)

      1/8/24 8:10:38 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Synthetic Biologics Inc.

      10-Q - Theriva Biologics, Inc. (0000894158) (Filer)

      11/13/23 8:15:58 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

      Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value Believes Rumored Brookfield Transaction Substantially Undervalues Grifols Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107873955/en/Historical Forward EV/EBITDA Multip

      11/8/24 3:54:00 PM ET
      $GRFS
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synthetic Biologics Rebrands as Theriva Biologics

      ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE:TOVX), ("Theriva" or the "Company") is the new name of Synthetic Biologics, Inc. (NYSE:SYN). The new name, logo and branding elements were introduced to better reflect Theriva's position as a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet need. In addition, the Company announced its common stock is expected to begin trading on NYSE American under the new ticker symbol "TOVX" on Thursday, October 13, 2022. "The rebranding solidifies our strategic transformation and reflects our sharpened focus on advancing unique, oncoly

      10/12/22 8:00:00 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

      - The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 - ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a positive outcome from the Data and Safety Monitoring Committee (DSMC) review of results from the first Cohort of its Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host

      9/27/22 8:00:00 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Synthetic Biologics Inc. (Amendment)

      SC 13G/A - Synthetic Biologics, Inc. (0000894158) (Subject)

      2/23/22 4:42:27 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synthetic Biologics Inc. (Amendment)

      SC 13G/A - Synthetic Biologics, Inc. (0000894158) (Subject)

      2/4/22 4:23:58 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed

      SC 13D/A - Synthetic Biologics, Inc. (0000894158) (Subject)

      3/2/21 3:33:11 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYN
    Leadership Updates

    Live Leadership Updates

    See more
    • Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

      Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value Believes Rumored Brookfield Transaction Substantially Undervalues Grifols Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107873955/en/Historical Forward EV/EBITDA Multip

      11/8/24 3:54:00 PM ET
      $GRFS
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results

      ROCKVILLE, Md., March 4, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the year ended December 31, 2020. Recent developments: Received Institutional Review Board ("IRB") approval from Washington University School of Medicine in St. Louis for the SYN-004 (ribaxamase) Phase 1b/2a clinical trial protocol in allogeneic hematopoietic cell transplant ("HCT") recipients Commenced screening of patients for enrollment of the f

      3/4/21 4:10:00 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYN
    Financials

    Live finance-specific insights

    See more
    • Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

      -Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call and webcast to be held today at 8:30 a.m. ET- ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update. "We are pleased with the steady progress th

      8/11/22 8:00:00 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results

      ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, August 11, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide a corporate update. Individuals may participate in the live call via telephone by dialing (800) 289-0571 (domestic) or (929) 477-0324 (international) and using the conference ID: 7145566. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and the public can acces

      8/4/22 8:00:00 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

      -Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- - Reported positive safety data on SYN-020 intestinal alkaline phosphatase from the Phase 1 Multiple Ascending Dose clinical trial- -Formed Scientific Advisory Board and strengthened the leadership team to support transformative clinical development strategy and extension into oncology - -As of March 31, 2022, Synthetic Biologics reports $56.7 million in cash, which is expected to provide runway

      5/16/22 8:00:00 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Synthetic Biologics upgraded by Maxim Group

      Maxim Group upgraded Synthetic Biologics from Hold to Buy

      3/12/21 10:41:11 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care